The new rapid testing laboratory and jointly developed Thermo Scientific OmnipathTM Combi SARS-CoV-2 IgG ELISA test detects and quantifies antibodies against the coronavirus and increases the University of Oxford’s testing capacity to up to 50,000 tests per day. Oxford researchers are already using the new fully automated testing platform to provide weekly UK wide data for the Office of National Statistics as part of the national COVID-19 Infection Survey. The determination of antibody status aids in the diagnosis and surveillance of the disease during the acute and recovery stages of infection. Mark Stevenson, Executive Vice President and Chief Operating Officer at Thermo Fisher Scientific, said, 'Our ongoing partnership with Oxford University is key to enabling rapid scaling of novel diagnostics as we expand our COVID-19 response. Combining the academic research capabilities of world recognised scientists at Oxford University with our UK based development and manufacturing facility i
